Welcome to today's episode on the salience network, the final episode in our three-part series on neural networks. We'll explore how the salience network helps the brain prioritize what matters most by filtering relevant stimuli.

References:

• https://pmc.ncbi.nlm.nih.gov/articles/PMC2899886/

• https://www.nature.com/articles/s41398-018-0118-6

• https://www.nature.com/articles/s41598-022-15489-9

• https://pmc.ncbi.nlm.nih.gov/articles/PMC5913255/

On todays episode we will be discussing Transcranial Magnetic Stimulation with a very special guest, Dr. Jonathan Downar. We will also discuss the ONE-D and THREE-D trails.

Three-D Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30295-2/abstract’

One-D Trial: https://www.researchsquare.com/article/rs-5679327/v1

SAINT TMS: https://psychiatryonline.org/doi/10.1176/appi.ajp.2019.19070720

On today's episode, we continue our series with a discussion of the Central Executive Network, following our previous episode on the Default Mode Network.

References:

• https://pubmed.ncbi.nlm.nih.gov/30250390/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4162869/

• https://link.springer.com/article/10.3758/s13415-011-0083-5

• https://www.cell.com/neuron/comments/S0896-6273(06)00349-7

• https://pubmed.ncbi.nlm.nih.gov/18799601/

• https://www.nature.com/articles/s41386-021-01132-0

On today's episode we have a special international guest, Dr. Pouya Movahed Rad from Lund University in Sweden. We will be discussing Electroconvulsive therapy (ECT) and the Ket-ECT, and ELEKT-D studies.

Comparison: https://pubmed.ncbi.nlm.nih.gov/38114073/

Join us today as we venture into the Triple Network Model as a basis for psychiatric illness, starting with the Default Mode Network.

References

• https://pmc.ncbi.nlm.nih.gov/articles/PMC7959111/

• https://pubmed.ncbi.nlm.nih.gov/37167968/

• https://www.nature.com/articles/s42003-019-0611-3

• https://www.psychiatrictimes.com/view/mindwandering-mood-for-thought

• https://www.nature.com/articles/s41380-021-01403-8

• https://www.sciencedirect.com/science/article/abs/pii/S0167876022000071

• https://www.nature.com/articles/tp201740

• https://pubmed.ncbi.nlm.nih.gov/25938726/

Welcome back! Today we will be discussing Metformin and some of the recent guidelines published in the journal the Schizophrenia Bulletin. (Carolan et. al 2024).

On today’s special guest episode, we’ll be exploring the topic of nitrous oxide with Dr. Charles Conway and Dr. Vasilis Hristidis.

https://medicine.washu.edu/news/laughing-gas-relieves-symptoms-in-people-with-treatment-resistant-depression/

https://pmc.ncbi.nlm.nih.gov/articles/PMC5825282/

https://pubmed.ncbi.nlm.nih.gov/34108247/

https://pubmed.ncbi.nlm.nih.gov/25577164/

In today’s episode, we explore ketamine’s therapeutic potential with Dr. Joshua Rosenblat, a leading expert and faculty member at the University of Toronto’s Department of Psychiatry (learn more).

https://x.com/jd_rosenblat?lang=en

https://pubmed.ncbi.nlm.nih.gov/35688035/

https://pubmed.ncbi.nlm.nih.gov/39608193/

Welcome back! Today, we are discussing a new branded medication that combines bupropion with dextromethorphan for the treatment of depression.

Today, we will be discussing tricyclic antidepressants (TCA's). Once again, we've picked a few of our favorites to discuss on today's episode.